Pay in 4 interest-free payments of $6.06 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Micic, A
During phase 1 trials in NASH patients, efocipegtrutide showed a half-life of around 5.9 days, and was capable of reducing body weight by 5.1% when administered weekly at 0.08mg/kg, after 12 weeks [36]
SURMOUNT-5 Head-to-Head In 2025, Eli Lilly published the SURMOUNT-5 trial directly comparing tirzepatide (15 mg) and semaglutide (2.4 mg) in adults with obesity over 72 weeks
Even better results were seen when paired with healthy eating and physical activity
In these trials, all participants received instruction for an approximately 500 kcal/day deficit and physical activity counseling
Simple Peptide scores well here with phone, email, and social media channels staffed by responsive agents
